Biogen (0R1B) Share Forecast & Price Target
0R1B Analyst Ratings
0R1B Stock 12 Month Forecast
Average Price Target
$263.20▲(4.25% Upside)Detailed List of Analyst Forecasts
| Analyst Profile | Expert Firm | Price Target | Position | Upside / Downside | Action | Date | Follow | Article |
|---|---|---|---|---|---|---|---|---|
| Jason Zemansky | Bank of America Securities | $257 | hold | 1.79%Upside | Reiterated | 10/29/26 | ||
| Geoff Meacham | Citi | $215→$255 | hold | 1.00%Upside | Reiterated | 10/29/26 | ||
| Phil Nadeau | TD Cowen | $250→$260 | buy | 2.98%Upside | Assigned | 10/29/26 | ||
| Mohit Bansal | Wells Fargo | $310 | buy | 22.79%Upside | Reiterated | 10/29/26 | ||
| Brian Skorney | Robert W. Baird | $250→$290 | buy | 14.87%Upside | Reiterated | 10/29/26 | ||
| Ami Fadia | Needham | $256→$290 | buy | 14.87%Upside | Reiterated | 10/29/26 | ||
| Sumant Kulkarni | Canaccord Genuity | $248→$272 | buy | 7.74%Upside | Reiterated | 10/29/26 | ||
| Evan Seigerman | BMO Capital | $220→$250 | hold | -0.98%Downside | Reiterated | 10/29/26 | ||
 Unknown AnalystNot Ranked | Leerink Partners | $260 | buy | 2.98%Upside | Reiterated | 10/29/26 | ||
| Laura Chico | Wedbush | $212→$225 | hold | -10.88%Downside | Reiterated | 10/29/26 | ||
| Michael Yee | UBS | $270→$300 | buy | 18.83%Upside | Assigned | 10/29/26 | ||
| Terence Flynn | Morgan Stanley | $238→$231 | hold | -8.50%Downside | Assigned | 10/29/26 | ||
| Jasper Hellweg | Argus Research | $280 | buy | 10.90%Upside | Upgraded | 10/29/26 | ||
| Ilya Zubkov | Freedom Capital Markets | $255→$275 | buy | 8.92%Upside | Reiterated | 10/29/26 | ||
| Paul Matteis | Stifel Nicolaus | $242→$286 | buy | 13.28%Upside | Reiterated | 10/29/26 |
| Analyst Profile | Date | Price Target | Position | Upside / Downside | Action | Follow | Article | Expert Firm |
|---|---|---|---|---|---|---|---|---|
| Jason Zemansky | 10/29/26 | $257 | hold | 1.79%Upside | Reiterated | Bank of America Securities | ||
| Geoff Meacham | 10/29/26 | $215→$255 | hold | 1.00%Upside | Reiterated | Citi | ||
| Phil Nadeau | 10/29/26 | $250→$260 | buy | 2.98%Upside | Assigned | TD Cowen | ||
| Mohit Bansal | 10/29/26 | $310 | buy | 22.79%Upside | Reiterated | Wells Fargo | ||
| Brian Skorney | 10/29/26 | $250→$290 | buy | 14.87%Upside | Reiterated | Robert W. Baird | ||
| Ami Fadia | 10/29/26 | $256→$290 | buy | 14.87%Upside | Reiterated | Needham | ||
| Sumant Kulkarni | 10/29/26 | $248→$272 | buy | 7.74%Upside | Reiterated | Canaccord Genuity | ||
| Evan Seigerman | 10/29/26 | $220→$250 | hold | -0.98%Downside | Reiterated | BMO Capital | ||
| Unknown AnalystNot Ranked | 10/29/26 | $260 | buy | 2.98%Upside | Reiterated | Leerink Partners | ||
| Laura Chico | 10/29/26 | $212→$225 | hold | -10.88%Downside | Reiterated | Wedbush | ||
| Michael Yee | 10/29/26 | $270→$300 | buy | 18.83%Upside | Assigned | UBS | ||
| Terence Flynn | 10/29/26 | $238→$231 | hold | -8.50%Downside | Assigned | Morgan Stanley | ||
| Jasper Hellweg | 10/29/26 | $280 | buy | 10.90%Upside | Upgraded | Argus Research | ||
| Ilya Zubkov | 10/29/26 | $255→$275 | buy | 8.92%Upside | Reiterated | Freedom Capital Markets | ||
| Paul Matteis | 10/29/26 | $242→$286 | buy | 13.28%Upside | Reiterated | Stifel Nicolaus |
Best Analysts Covering Biogen
Copying Salveen Richter's trades and holding each position for 3 Months would result in 59.26% of your transactions generating a profit, with an average return of +2.08% per trade.
Copying Myles Minter's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +22.10% per trade.
Copying Myles Minter's trades and holding each position for 2 Years would result in 65.22% of your transactions generating a profit, with an average return of +25.16% per trade.
0R1B Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 41 | 54 | 40 | 36 | 34 |
| Hold | 32 | 34 | 23 | 22 | 14 |
| Sell | 0 | 1 | 1 | 2 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 73 | 89 | 64 | 60 | 49 |
In the current month, 0R1B has received 34 Buy Ratings, 14 Hold Ratings, and 1 Sell Ratings. 0R1B average Analyst price target in the past 3 months is 263.20.
0R1B Financial Forecast
0R1B Earnings Forecast
Next quarter’s earnings estimate for 0R1B is $2.86 with a range of $2.45 to $3.87. The previous quarter’s EPS was $2.62. 0R1B beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0R1B has Performed in-line its overall industry.
0R1B Sales Forecast
Next quarter’s sales forecast for 0R1B is $2.58B with a range of $2.47B to $2.67B. The previous quarter’s sales results were $2.69B. 0R1B beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0R1B has Performed in-line its overall industry.